There are a handful of upsides to Recursion merging with Exscientia. First, all of Exscientia's pipeline programs will become Recursion's, which gives it that many more opportunities to commercialize ...
Two AI-driven disruptors, one biotech-focused, one software-first, post double-digit growth but diverge sharply on risk, cash flow, and valuation.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results